Small molecule modulators in epigenetics: Implications in gene expression and therapeutics

Subcellular Biochemistry

Volumn 41, Issue , 2007, Pages 397-428

  Swaminathan, V ^a   Reddy, B A Ashok ^a   Ruthrotha Selvi, B ^a   Sukanya, M S ^a   Kundu, Tapas K ^a  

^a JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DNA (CYTOSINE 5) METHYLTRANSFERASE; DRUG CARRIER; ENZYME INHIBITOR; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE LYSINE METHYLTRANSFERASE; PROTAMINE KINASE;

ACETYLATION; ANIMAL; DNA METHYLATION; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; METHYLATION; NEOPLASM; PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; RUBINSTEIN SYNDROME;

ACETYLATION; ANIMALS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DRUG CARRIERS; ENZYME INHIBITORS; EPIGENESIS, GENETIC; GENE EXPRESSION; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; METHYLATION; NEOPLASMS; PHOSPHORYLATION; PROTAMINE KINASE; PROTEIN PROCESSING, POST-TRANSLATIONAL; RUBINSTEIN-TAYBI SYNDROME;

EID: 34249828678     PISSN: 03060225     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (160)

1. Ahmad K, Henikoff S (2002) The histone variant H3. 3 marks active chromatin by replication-independent nucleosome assembly. Mol Cell 9: 1191-1200.
2. Akimaru H, Chen Y, Dai P, Hou DX, Nonaka M, Smolik SM, Armstrong S, Goodman RH, Ishii S (1997) Drosophila CBP is a co-activator of cubitus interruptus in hedgehog signaling. Nature 386: 735-738.
3. Amur SG, Shanker G, Cochran JM, Ved HS, Pieringer RA (1986) Correlation between inhibition of myelin basic protein (arginine) methyltransferase by sinefungin and lack of compact myelin formation in cultures of cerebral cells from embryonic mice. J Neurosci Res 16: 367-376.
4. An W, Kim J, Roeder RG (2004) Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell117: 735-748.
5. Andrews KT, Walduck A, Kelso MJ, Fairlie DP, Saul A, Parsons PG (2000) Antimalarial effect of histone deacetylation inhibitors and mammalian tumor cytodifferentiating agents. Int J Paarasitol 30: 761-768.
6. Atadja P, Hsu M, Kwon P, Trogani N, Bhalla K, Remiszewski S (2004) Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824. Novartis Found Symp 259: 249-266.
7. Balasubramanyam K, Swamninathan V, RAnganathan A, Kundu TK (2003) Small molecule modulators of histone acetyltransferase p300. J Biol Chem 278: 19134-19140.
8. Balasubramanyam K, Altaf M, Varier RA, Swaminathan V, Ravindran A, Sadhale PP, Kundu TK (2004) Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J Biol Chem 279: 33716-33726.
9. Balasubramanyam K, Varier RA, Altaf M, Swaminathan V, Siddappa NB, Ranga UK, Kundu TK (2004) Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone avetyltransferase-dependent chromatin transcription. J Biol Chem 279: 51163-51171.
10. Bali P, George P, Cohen P, Tao J, Guo F, Sigua C, Vishvanath A, Scuto A, Annavarapu S, Fiskus W, Moscinski L, Atadja P, Bhalla K (2004) Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin Cancer Res 10: 4991-4997.
11. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumarawsamy S, Boyapalle S, Atadja P, Seto E, Bhalla K (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.: J Biol Chem 280(29): 26729-26734.
12. Bannister AJ, Schneider R, Kouzarides T (2002) Histone methylation: Dynamic or static? Cell 109: 801-806.
13. Bedalov A, Gatbonton T, Irvine WP, Gottschling DE, Simon JA (2001) Identification of a small molecule inhibitor of Sir2p. Proc Natl Acad Sci USA 98(26): 15113-15118.
14. Bedford MT, Richard S (2005) Arginine methylation an emerging regulator of protein function. Mol Cell 18: 263-272.
15. Belli SI (2000) Chromatin remodelling during life cycle of trypanosomatids. Int J Parasitol 30: 679-687.
16. Berger SL, Sterner DE (2000) Acetylation of histones and transcription-related factors, microbiology and molecular biology reviews, June 435-459.
17. Bertos NR, Wang AH, Yang XY (2001) Class II histone deacetylases: Structure, function, and regulation. Biochem Cell Biol 79: 243-252.
18. Biel M, Kretsovali A, Karatzali E, Papamatheakis J, Giannis A (2004) Design, synthesis, and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase Gcn5. Angew Chem Int Ed Engl 43(30): 3974-3976.
19. Blander G, Guarente L (2004) The Sir2 family of protein deacetylases. Annu Rev of Biochem 73: 417-435.
20. Brinkmann H, Dahler AL, Popa C, Serewko MM, Parsons PG, Gabrielli BG, Burgess AJ, Saunders NA (2001) Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts. J Biol Chem 276: 22491-22499.
21. Brush MH, Guardiola A, Connor JH, Yao TP, Shenolikar S (2004) Deacetylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases. J Biol Chem 279: 7685-7691.
22. Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ (2001) ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 276: 42462-42467.
23. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM (2000) Suberoylanilide hydroxamic acid: An inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60: 5165-5170.
24. Butler LM, Webb Y, Agus DB, Higgins B, Tolentino TR, Kutko MC, LaQuaglia MP, Drobnjak M, Cordon-Cardo C, Scher HI, Breslow R, Richon VM, Rifkind RA, Marks PA (2001) Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res 7(4): 962-970.
25. Canettieri G, Morantte I, Guzman E, Asahara H, Herzig S, Anderson SD, Yates JR 3rd, Montminy M (2003) Attenuation of a phosphorylation-dependent activator by an HDAC-PP1 complex. Nat Struct Biol 10: 175-181.
26. Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D, Munshi NC, Schlossman R, Richardson P, Griffin J, Anderson KC (2003) NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 102(7): 2615-2622.
27. Chan HM, Kastic-Demonacos M, Smith L, Demonacos C, La Thangue NB (2001) Acetylation control of the retinoblastoma tumour-suppressor protein. Nat Cell Biol 3: 667-674.
28. Chang JH, Kim HC, Hwang KY, Lee JW, Jackson SP, Bell SD, Cho Y (2002) Structural basis for the NAD dependent deacetylase mechanism of Sir 2. J Biol Chem 277: 34489-34498.
29. Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN (2004) Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 24: 8467-8476.
30. Chen CS, Weng SC, Tseng PH, Lin HP, Chen CS (2005) Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 280: 38879-38887.
31. Cheng D, Yadav N, King RW, Swanson MS, Weinstein EJ, Bedford MT (2004) Small molecule regulators of protein arginine methyltransferases. J Biol Chem 279: 23892-23899.
32. Cheung P, Tanner KG, Cheung WL, Sassone-Corsi P, Denu JM, Allis CD (2000) Synergistic coupling of histone H3 phosphorylation and acetylation in response to epidermal growth factor stimulation. Mol Cell 5: 905-915.
33. Covic M, Hassa PO, Saccani S, Buerki C, Meier NI, Lombardi C, Imhof R, Bedford MT, Natoli G, Hottiger MO (2005) Arginine methyltransferase CARM1 is a promoter-specific regulator of NFkappaB-dependent gene expression. EMBO J 24: 85-96.
34. Cuthbert GL, Daujat S, Snowden AW, Erdjument-Bromage H, Hagiwara T, Yamada M, Schneider R, Gregory PD, Tempst P, Bannister AJ, Kouzarides T (2004) Histone deimination antagonizes arginine methylation. Cell 118: 545-553.
35. Dailey LA, Jekel N, Fink L, Gessler T, Schmehl T, Wittmar M, Kissel T, Seeger W (2006) Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol Appl Pharmacol (in press).
36. Darkin-Rattray SJ, Gurnett AM, Myers RW, Dulski PM, Crumley TM, Allocco JJ, Cannova C, Meinke PT, Colletti SL, Bednarek MA, Singh SB, Goetz MA, Dombrowski AW, Polishook JD, Schmatz DM (1996) Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc Natl Acad Sci USA 93(23): 13143-13147.
37. Dasmahapatra G, Almenara JA, Grant S (2006) Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2. Mol Pharmocol 69: 288-298.
38. Daujat S, Bauer UM, Shah V, Turner B, Berger S, Kouzarides T (2002) Crosstalk between CARM1 methylation and CBP acetylation on histone H3. Curr Biol 12: 2090-2097.
39. de Ruijter AJ, Leen R, Hoebink J, Caron HN, van Kuilenburg AB (2006) Antagonistic effects of sequential administration of BL1521, a histone deacetylase inhibitor, and gemcitabine to neuroblastoma cells. Cancer Lett 233: 240-246.
40. De Smet C, Lurquin C, Lethé B, Martelange V, Boon T (1999) DNA methylation is the primary silencing mechanism for a set of germ line-and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 19: 7327-7335.
41. Dong Z, Bode AM (2006) The role of histone H3 phosphorylation (Ser10 and Ser28) in cell growth and cell transformation. Mol Carcinog 45: 416-421.
42. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC (2005) Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45: 495-528.
43. Eberharter A, Becker PB (2002) Histone acetylation: A switch between repressive and permissive chromatin. EMBO reports 3: 224-229.
44. Esteller M, Corn PG, Baylin SB, Herman JG (2001) A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229.
45. Fenrick R, Hiebert SW (1998) Role of histone deacetylase in acute leukemia. J Cell Biochem 31: 194-202.
46. Fischle W, Kiermer V, Dequiedt F, Verdin E (2001) The emerging role of class II histone deacetylases. Biochem Cell Biol 79: 337-348.
47. Forneris F, Binda C, Vanoni MA, Battaglioli E, Mattevi A (2005) Human histone demethylase LSD1 reads the histone code. J Biol Chem 280: 41360-41365.
48. Frye RA (2000) Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun 273: 793-798.
49. Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, Wang HG, Atadja P, Bhalla K (2003) Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2: 971-984.
50. Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S (2001) Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci USA 98(1): 87-92.
51. Gao L, Cueto MA, Asselbergs F, Ataoja P (2002) Cloning and functional characterization of HDAC11: A novel member of the human histone deacetylase family. J Biol Chem 277: 25748-25755.
52. Garcia-Manero G, Issa JP (2005) Histone deacetylase inhibitors: A review of their clinical status as antineoplastic agents. Cancer Invest 23: 635-642.
53. George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P, Bhalla K (2005) Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 105(4): 1768-1776.
54. Gibbons RJ (2005) Histone modifying and chromatin remodeling enzymes in cancer and dysplastic syndromes. Hum Mol Genet 14: R85-R92.
55. Gray SG, Ekstrom TJ (2001) The human histone deacetylase family. Exp Cell Res 262: 75-83.
56. Greiner D, Bonaldi T, Eskeland R, Roemer E, Imhof A (2005) Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat Chem Biol1: 143-145.
57. Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL (2001) Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem 276(42): 38837-38843.
58. Grozinger CM, Hassig CA, Schreiber SL (1999) Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc Natl Acad Sci USA 96: 4868-4873.
59. Grozinger CM, Schreiber SL (2000) Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc Natl Acad Sci USA 97: 7835-7840.
60. Gusterson R, Brar B, Faulkes D, Giordano A, Chrivia J, Latchman D (2002) The transcriptional co-activators CBP and p300 are activated via phenylephrine through the p42/p44 MAPK cascade. J Biol Chem 277: 2517-2524.
61. Hake SB, Xiao A, Allis CD (2004) Linking the epigenetic 'language' of covalent histone modifications to cancer. Br J Cancer 90: 761-769.
62. Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, Yagyu R, Nakamura Y (2004) SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 6: 731-740.
63. He L-Z, Tolentino T, Grayson P. Zhong S, Warrell RP Jr, Rifkind RA, Marks PA, Richon VM, Pandolfi PP (2001) Histone deacetylase inhibitors induce remission in transgenic models of therapyresistant acute promyelocytic leukemia. J Clin Invest 108: 321-330.
64. Heltweg B, Gatbonton T, Schuler AD, Posakony J, Li H, Goehle S, Kollipara R, Depinho RA, Gu Y, Simon JA, Bedalov A (2006) Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 66(8): 4368-4377.
65. Hennessy BT, Garcia-Manero G, Kantarjian HM, Giles FJ (2003) DNA methylation in haematological malignancies: the role of decitabine. Expert Opin Investig Drugs 12: 1985-1993.
66. Hong H, Kao C, Jeng MH, Eble JN, Koch MO, Gardner TA, Zhang S, Li L, Pan CX, Hu Z, MacLennan GT, Cheng L (2004) Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer 101: 83-89.
67. Hook SS, Orian A, Cowley SM, Eisenman RN (2002) Histone deacetylase 6 binds polyubiquitin through its zinc finger (PAZdomain) and co purifies with deubiquitinating enzymes. Proc Natl Acad Sci USA 99: 13425-13430.
68. Impagnatiello F, Guidotti AR, Pesold C, Dwivedi Y, Caruncho H, Pisu MG, Uzunov DP, Smalheiser NR, Davis JM, Pandey GN, Pappas GD, Tueting P, Sharma RP, Costa E (1998) A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc Natl Acad Sci USA 95: 15718-15723.
69. Jackson MD, Schmidt MT, Oppenheimer NJ, Denu JM (2003) Mechanism of nicotinamide inhibition and transglycosidation by Sir2 histone/protein deacetylases. J Biol Chem 278(51): 50985-50998.
70. Johnstone RW, Licht JD (2003) Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target? Cancer Cell 4: 13-18.
71. Joseph J, Mudduluru G, Antony S, Vashistha S, Ajitkumar P, Somasundaram K (2004) Expression profiling of sodium butyrate (NaB)-treated cells: Identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB. Oncogene 23: 6304-6315.
72. Kao H-Y, Lee C-H, Komarov A (2002) Isolation and characterization of mammalian HDAC10: A novel histone deacetylase. J Biol Chem 277: 187-193.
73. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP (2003) The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115: 727-738.
74. Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T (1993) Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem 268(30): 22429-22435.
75. Kim A, Dean A (2004) Developmental stage differences in chromatin subdomains of the α-globin locus. Proc Natl Acad Sci USA 101: 7028-7033.
76. Kim YB, Lee KH, Sugita K, Yoshida M, Horinouchi S (1999) Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 18(15): 2461-2470.
77. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F (2003) Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63: 7291-7300.
78. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100: 11606-11611.
79. Kontermann RE (2006) Immunoliposomes for cancer therapy. Curr Opin Mol Ther 8: 39-45.
80. Kornblith AB, Herndon JE II, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, Powell BL, DeCastro C, Ellerton J, Larson RA, Schiffer CA, Holland JC (2002) Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A cancer and leukemia group B study. J Clin Oncol 20: 2441-2452.
81. Kouzarides T (2000) Acetylation: A regulatory modification to rival phosphorylation? EMBO J 19: 1176-1179.
82. Kraker AJ, Mizzen CA, Hartl BG, Miin J, Allis CD, Merriman RL (2003) Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma. Mol Cancer Ther 2(4): 401-408.
83. Kramer OH, Gottlicher M, Heinzel T (2001) Histone deacetylase as a therapeutic target. Trends Endocrinol Metab 12: 294-300.
84. Kubicek S, Jenuwein T (2004) A crack in histone lysine methylation. Cell 119: 903-906.
85. Kwon HJ, Kim JH, Kim M, Lee JK, Hwang WS, Kim DY (2003) Anti-parasitic activity of depudecin on Neospora caninum via the inhibition of histone deacetylases. Vet Parasitol 112: 269-276.
86. Lau OD, Kundu TK, Soccio RE, Ait-Si-Sli S, Khail EM, Vassilev A, Wolffe AP, Nakatani Y, Roeder RG, Cole PA (2000) HATs off: Selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol Cell 5: 589-595.
87. Lee CC, MacKay JA, Frechet JM, Szoka FC (2005) Designing dendrimers for biological applications. Nat Biotechnol 23: 1517-1526.
88. Littau VC, Allfrey VG, Frenster JH, Mirsky AE (1964) Active and inactive regions of nuclear chromatin as revealed by electron microscope autoradiography. Proc Natl Acad Sci USA 52: 93-100.
89. Longmuir KJ, Robertson RT, Haynes SM, Baratta JL, Waring AJ (2006) Effective targeting of liposomes to liver and hepatocytes in vivo by incorporation of a Plasmodium amino acid sequence. Pharm Res 23: 759-769.
90. Luo J, Su F, Chen D, Shiloh A, Gu W (2000) Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408: 377-381.
91. Maggio SC, Rosato RR, Kramer LB, DaiY, Rahmani M, Paik DS, CzarnikAC, Payne SG, Spiegel S, Grant S (2004) The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res 64: 2590-2600.
92. Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S, Le Villain JP, Troalen F, Trouche D, Harel-Bellan A (1998) Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature 391: 601-605.
93. Mahmoudi T, Verrijzer CP (2001) Chromatin silencing and activation by Polycomb and trithorax group proteins. Oncogene 20: 3055-3066.
94. Mai A, Massa S, Rotili D, Cerbara I, Valente S, Pezzi R, Simeoni S, Ragno R (2005) Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 25: 261-309.
95. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN (2005) In vivo synergy between topoisomerase II and histone deacetylase inhibitors: Predictive correlates. Mol Cancer Ther 4: 1993-2000.
96. Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN (2005) Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clin Cancer Res 11: 8467-8475.
97. Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN (2004) Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 92: 223-237.
98. Marks PA, Rifkind RA, Richon VM (2000) Deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer I 92: 1210-1216.
99. Marks PA, Richon VM, Breslow R (2001) Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13: 477-485.
100. Martin C, Zhang Y (2005) The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol 6: 838-849.
101. Michaelis M, Michaelis UR, Fleming I, Suhan T, Cinatl J, Blaheta RA, Hoffmann K, Kotchetkov R, Busse R, Nau H, Cinatl J Jr (2004) Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 65: 520-527.
102. Mishra S, Saleh A, Espino PS, Davie JR, Murphy LJ (2006) Phosphorylation of histones by tissue transglutaminase. J Biol Chem 281: 5532-5538.
103. Mishra V, Mahor S, Rawat A, Gupta PN, Dubey P, Khatri K, Vyas SP (2006) Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J Drug Target 14: 45-53.
104. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, Anderson KC (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proc Natl Acad Sci USA 101: 540-545.
105. Moore SDP, Herrick SR, Ince TA, Klienman MS, Cin PD, Morton C, Quade BJ, 2000; Uterine Leiomyomata with t(10; 17) disrupt the histone acetyltransferase MORF. Cancer Res 61: 5570-5577.
106. Morales V, Richard-Foy H (2000) Role of Histone N-Terminal Tails and Their Acetylation in Nucleosome Dynamics. Mol Cell Biol 20: 7230-7237.
107. Murphy M, Ahn J, Walker KK (1999) Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 13: 2490-2501.
108. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S (1998) FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 241(1): 126-133.
109. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, Alvarez R, Schiavone EM, Ferrara F, Bresciani F, Weisz A, de Lera AR, Gronemeyer H, Altucci L (2005) Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nature Med 11: 77-84.
110. Nielsen SJ, Schneider R, Bauer UM, Bannister AJ, Morrison A, O'Carroll D, Firestein R, Cleary M, Jenuwein T, Herrera RE, Kouzarides T (2001) Rb targets histone H3 methylation and HP1 to promoters. Nature 412: 561-565.
111. Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K (2003) Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Ablpositive human acute leukemia cells. Blood 101: 3236-3239.
112. Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield VM, Su L, Xu G, Zhang Y (2005) hDOT1L links histone methylation to leukemogenesis. Cell. 121: 167-178.
113. Pal S, Vishwanath SN, Erdjument-Bromage H, Tempst P, Sif S (2004) Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol 24: 9630-9645.
114. Parson PG, Hansen C, Fairlie DP, West ML, Danoy PA, Sturm RA, Dunn IS, Pedley J, Ablett EM (1997) Tumor selectivity and transcriptional activation by azelaic bishydroxamic acid in human melanocytic cells. Biochem Pharmacol 53: 1719-1724.
115. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, Holloway AJ, Johnstone RW (2005) Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 3697-3702.
116. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276(39): 36734-36741.
117. Popovic N, Brundin P (2006) Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases. Int J Pharm 314: 120-126.
118. Qui L, Kelso MJ, Hansen C, West ML, Fairlie DP, Parson PG (1999) Antitumor activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer 80: 1252-1258.
119. Rea S, Eisenhaber F, O'Carroll D, Strahl BD, Sun ZW, Schmid M, Opravil S, Mechtler K, Ponting CP, Allis CD, Jenuwein T (2000) Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 406: 593-599.
120. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95(6): 3003-3007.
121. Rocchi P, Tonelli R, Camerin C, Purgato S, Fronza R, Bianucci F, Guerra F, Pession A, Ferreri AM (2005) p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Oncol Rep 13: 1139-1144.
122. Rouaux C, Loeffler JP, Boutillier AL (2004) Targeting CREB-binding protein (CBP) loss of function as a therapeutic strategy in neurological disorders. Biochem Pharmacol 68: 1157-1164.
123. Roy S, Packman K, Jeffrey R, Tenniswood M (2005) Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ 12: 482-491.
124. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O (1999) A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 96(8): 4592-4597.
125. Schneider R, Bannister AJ, Myers FA, Thorne AW, Crane-Robinson C, Kouzarides T (2004) Histone H3 lysine 4 methylation patterns in higher eukaryotic genes. Nature 6: 73-77.
126. Schwartz BE, Ahmad K (2005) Transcriptional activation triggers deposition and removal of the histone variant H3. 3. Genes Dev 19: 804-814.
127. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi Y (2004) Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119: 941-953.
128. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group. B J Clin Oncol 20: 2429-2440.
129. Song F, Smith JF, Kimura MT, Morrow AD, Matsuyama T, Nagase H, Held WA (2005) Association of tissue-specific differentially methylated regions (TDMs) with differential gene expression, Proc Natl Acad Sci USA 102: 3336-3341.
130. Steinfeld U, Pauli C, Kaltz N, Bergemann C, Lee HH (2006) T lymphocytes as potential therapeutic drug carrier for cancer treatment. Int J Pharm 311: 229-236.
131. Stiff T, O'Driscoll M, Rief N, Iwabuchi K, Lobrich M, Jeggo PA (2004) ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res 64: 2390-2396.
132. Stimson L, Rowlands MG, Newbatt YM, Smith NF, RAynaud FI, Rogers P, BAvetsias V, Gorsuch S, Jarman M, Bannister A, Kouzarides T, McDOnald E, Workman P, Aherne GW (2005) Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Mol Cancer Ther 4: 1521-1532.
133. Strahl BD, Allis CD (2000) The language of covalent histone modifications. Nature 403: 41-45.
134. Su GH, Sohn TA, Ryu B, Kern SE (2000) A novel histone deacetylase inhibitor identified by highthroughput transcriptional screening of a compound library. Cancer Res 60(12): 3137-3142.
135. Subramanian C, Opipari AW Jr, Bian X, Castle VP, Kwok RP (2005) Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 4842-4847.
136. Sun ZW, Allis CD (2002) Ubiquitination of histone H2B regulates H3 methylation and gene silencing in yeast. Nature 418: 104-108.
137. Taki T, Sako M, Tsuchida M, Hayashi Y (1997) The t(11; 16)(q23; p13) translocation in Myelodysplastic syndrome fuses the MLL gene to the CBP gene. Blood 89: 3945-3950.
138. Tanaka Y, Naruse I, Maekawa T, Masuya H, Shiroishi T, Ishii S (1997) Abnormal skeletal patterning in embryos lacking a single Cbp allele: A partial similarity with Rubinstein-Taybi syndrome. Proc Natl Acad Sci USA 94: 10215-10220.
139. van Attikum H, Gasser SM (2005) The histone code at DNA breaks: A guide to repair? Nat Rev Mol Cell Biol 6: 757-765.
140. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629.
141. Varier RA, Kundu TK (2006) Chromatin modifications (acetylation/deacetylation/methylation) as new targets for HIV therapy. Curr Pharm Des 12: 1975-1993.
142. Vertino PM, Sekowski JA, Coll JM, Applegren N, Han S, Hickey RJ, Malkas LH (2002) DNMT1 is a component of a multiprotein DNA replication complex. Cell Cycle 1: 416-423.
143. Vidali G, Boffa LC, Bradbury EM, Allfrey VG (1978) Butyrate suppression of histone deacetylation leads to accumulation of multiacetylated forms of histones H3 and H4 and increased DNase I sensitivity of the associated DNA sequences. Proc Natl Acad Sci USA 75(5): 2239-2243.
144. Vigushin DM, Coombes RC (2002) Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13: 1-13.
145. Wang H, Huang ZQ, Xia L, Feng Q, Erdjument-Bromage H, Strahl BD, Briggs SD, Allis CD, Wong J, Tempst P, Zhang Y (2001) Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor. Science 293: 853-857.
146. Wang Y, Wysocka J, Sayegh J, Lee YH, Perlin JR, Leonelli L, Sonbuchner LS, McDonald CH, Cook RG, DouY, Roeder RG, Clarke S, StallcupMR, Allis CD, CoonrodSA(2004)HumanPAD4regulates histone arginine methylation levels via demethylimination. Science 306(5694): 279-283.
147. West KR, Otto S (2005) Reversible covalent chemistry in drug delivery. Curr Drug Discov Technol 2: 123-160.
148. Yang XJ, Gregoire S (2005) Class II histone deacetylases: From sequence to function, regulation, and clinical implication. Mol Cell Biol 25: 2873-2884.
149. Yang XY, Seto E (2003) Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression. Curr Opin Genet Dev 13: 143-153.
150. Yao TP, Suk P Oh, Fuchs M, Nai-Dong Zhou, Lian-Ee Ch'ng, Newsome D, Bronson RT, En Li, Livingston DM, Eckner R (1998) Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 93: 361-372.
151. Yarden RI, Brody LC (1999) BRCA1 interacts with components of the histone deacetylase complex. Proc Natl Acad Sci USA 96: 4983-4988.
152. Yih TC, Al-Fandi M (2006) Engineered nanoparticles as precise drug delivery systems. J Cell Biochem 97: 1184-1190.
153. Yoder JA, Walsh CP, Bestor TH (1997) Cytosine methylation and the ecology of intragenomic parasites. Trends Genet 13: 335-340.
154. Yoon HG, Chan DW, Huang ZQ, Li J, Fondell JD, Quin J, Wong J (2003) Purification and functional characterization of the human N-CoR complex: The roles of HDAC3, TBL1, and TBLR1. EMBO J 22: 1336-1346.
155. Yoshida M, Kijima M, Akita M, Beppu T (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265(28): 17174-17179.
156. Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S (2003) The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Ablþ cells sensitive and resistant to STI571. Blood 102: 3765-3774.
157. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN (2002) Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110: 479-488.
158. Zhang K, Dent SY (2005) Histone modifying enzymes and cancer: Going beyond histones. J Cell Biochem 96: 1137-1148.
159. Zhang Y, Adachi M, Zhao X, Kawamura R, Imai K (2004) Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino-methyl]benzamide and mcarboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells. Int J Cancer 110: 301-308.
160. Zhang Y, Reinberg D (2001) Transcription regulation by histone methylation: Interplay between different covalent modifications of the core histone tails. Genes Dev 15: 2343-2360.